as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹431.9
Change
+9.65 (2.29%)
Open
₹422.95
Prev. Close
₹422.25
Day High
₹436.0
Day Low
₹417.55
Volume Analysis
Traded
47,566
Delivered
24,494
Delivery %
51.49%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Below-average fundamentals quality score (49/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹457.86 | ₹446.93 | ₹439.41 | ₹428.48 | ₹420.96 | ₹410.03 | ₹402.51 |
| Fibonacci | ₹446.93 | ₹439.88 | ₹435.53 | ₹428.48 | ₹421.43 | ₹417.08 | ₹410.03 |
| Camarilla | ₹436.97 | ₹435.28 | ₹433.59 | ₹428.48 | ₹430.21 | ₹428.52 | ₹426.83 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+26.51%
1 Week
-11.31%
1 Month
+10.89%
3 Months
+0.09%
6 Months
+47.05%
1 Year
+26.05%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹114.43
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
15.31%
Net margin 7.75% × asset turnover 0.8x × equity multiplier 2.47x
Company Overview
Sector
Healthcare
Market Cap
₹4,415 Cr
P/E (TTM)
55.1
ROE
10.1%
Book Value
₹70.8
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Gufic Biosciences Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (79/100), while Valuation (11/100) is the weakest area to weigh before deciding. Notably: Below-average fundamentals quality score (49/100).
TopFund Score — Fundamentals Quality
49/100 — WeakData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 6.21 times its book value
- −Company has a low return on equity of 12.8% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Audio recording of earnings conference call held on November 16, 2026 uploaded on company website.
Newspaper advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 is attached herewith
Dr. Reeta Shah appointed Additional Independent Director from December 1, 2026, subject to shareholder approval.
Q2 FY26 results approved on Nov 14, 2026; standalone revenue ₹288.4 crore, net profit ₹23.5 crore.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 224 | 237 | 231 | 252 | 261 | 288 |
| Expenses + | 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 | 205 | 214 | 240 |
| Operating Profit | 39 | 36 | 34 | 36 | 39 | 34 | 26 | 33 | 38 | 33 | 47 | 47 | 48 |
| OPM % | 18.0% | 18.0% | 18.0% | 18.0% | 19.0% | 16.0% | 13.0% | 15.0% | 16.0% | 14.0% | 19.0% | 18.0% | 17.0% |
| Other Income + | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 | 1 |
| Interest | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 | 10 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit before tax | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 17 | 23 | 18 | 29 | 30 | 31 |
| Tax % | 25.0% | 25.0% | 26.0% | 26.0% | 26.0% | 26.0% | 27.0% | 24.0% | 26.0% | 30.0% | 24.0% | 26.0% | 25.0% |
| Net Profit + | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 13 | 17 | 12 | 22 | 22 | 23 |
| EPS in Rs | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | -5 | 3 | 5 | 10 | 16 | 11 | 23 | 17 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | 807 | 820 | 944 | 1,032 |
| Expenses + | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 631 | 556 | 657 | 684 | 793 | 857 |
| Operating Profit | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 148 | 135 | 150 | 136 | 151 | 175 |
| OPM % | 10.0% | 10.0% | 9.0% | 13.0% | 13.0% | 14.0% | 17.0% | 19.0% | 20.0% | 19.0% | 17.0% | 16.0% | 17.0% |
| Other Income + | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | 0 | 4 | 3 | 1 |
| Interest | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 | 17 | 25 | 37 | 38 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 19 | 22 | 17 | 21 | 31 | 31 |
| Profit before tax | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 | 116 | 94 | 87 | 108 |
| Tax % | 36.0% | 29.0% | 37.0% | 45.0% | 38.0% | 25.0% | 23.0% | 24.0% | 25.0% | 26.0% | 26.0% | 26.0% | — |
| Net Profit + | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 | 86 | 70 | 64 | 80 |
| EPS in Rs | 1 | 1 | 1 | 2 | 3 | 3 | 6 | 10 | 8 | 9 | 7 | 6 | 8 |
| Dividend Payout % | 9.0% | 5.0% | 4.0% | 2.0% | 2.0% | 2.0% | 2.0% | 1.0% | 1.0% | 1.0% | 1.0% | 2.0% | — |
| Sales growth | 22 | 36 | 22 | 25 | 15 | 8 | 29 | 60 | -11 | — | 2 | 15 | 18 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 | 523 | 591 | 655 | 700 |
| Borrowings + | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | 333 | 336 | 405 | 466 |
| Other Liabilities + | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | 227 | 232 | 273 | 276 |
| Total Liabilities | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,169 | 1,342 | 1,451 |
| Fixed Assets + | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | 159 | 506 | 491 | 480 |
| CWIP | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 | 307 | 22 | 22 | 52 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 9 |
| Other Assets + | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | 625 | 640 | 827 | 910 |
| Total Assets | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,169 | 1,342 | 1,451 |
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 11 | -4 | -4 | -5 | 5 | 47 | 87 | 106 | -27 | -7 | 123 | 45 |
| Cash from Investing Activity + | -2 | -1 | -5 | -9 | -13 | -43 | -7 | -95 | -191 | -102 | -71 | -31 |
| Cash from Financing Activity + | -5 | 5 | 7 | 14 | 8 | -4 | -79 | -6 | 234 | 82 | -37 | 32 |
| Net Cash Flow | 4 | 0 | -1 | 1 | 0 | 0 | 2 | 5 | 17 | -27 | 15 | 46 |
| Free Cash Flow | 9 | -5 | -8 | -13 | -8 | 7 | 75 | 19 | -214 | -116 | 52 | 14 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 92 | -8 | 2 | 30 | 33 | 110 | 115 | 94 | 1 | 13 | 107 | 38 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 25.29% | 25.17% | 24.89% | 24.75% | 24.2% | 23.79% | 23.81% | 23.51% | 23.3% | 23.23% | 23.36% | 23.66% |
| Promoters | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% | 72.5% | 72.5% | 72.5% | 72.5% | 72.5% |
| FII | 0.47% | 0.12% | 0.23% | 0.23% | 0.3% | 0.31% | 0.32% | 0.33% | 0.44% | 0.42% | 0.47% | 0.44% |
| DII | 1.72% | 2.2% | 2.38% | 2.51% | 2.99% | 3.39% | 3.38% | 3.66% | 3.74% | 3.83% | 3.67% | 3.38% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gufic Biosciences Ltd. (this stock) | 4,415 | 55.1 | 6.21 | 10.1% |
| Kwality Pharmaceuticals L | 4,370 | 45.3 | 11.31 | 22.6% |
| Zota Health Care Limited | 4,492 | — | 7.17 | -15.0% |
| Aarti Drugs Ltd. | 4,589 | 19.9 | 2.73 | 13.4% |
| Rpg Life Sciences Ltd | 4,220 | 36.8 | 6.13 | 19.3% |
| Gujarat Themis Biosyn Ltd | 4,659 | 239.0 | 4.55 | 16.2% |
| Sms Pharmaceuticals Ltd. | 4,758 | 40.7 | 5.64 | 14.3% |
Which Mutual Funds Hold Gufic Biosciences Ltd.?
Frequently Asked Questions about Gufic Biosciences Ltd.
Gufic Biosciences Ltd. (GUFICBIO) closed at ₹431.9 on NSE on 19 November 2026, up 9.65 (2.29%) from the previous close.
Gufic Biosciences Ltd. trades on the NSE (National Stock Exchange of India) under the symbol GUFICBIO.
Gufic Biosciences Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 55.1.
Gufic Biosciences Ltd. has a dividend yield of 0.02%.
Gufic Biosciences Ltd.'s 52-week high is ₹494.0 and its 52-week low is ₹268.0.
Gufic Biosciences Ltd. has a market capitalisation of ₹4,415 crore.
Gufic Biosciences Ltd. has a TopFund Quality Score of 49/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gufic Biosciences Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.